Figure 3
Figure 3. Overall survival according to CLLU1 expression levels in different prognostic subgroups for patients younger than 70 years at diagnosis. (A) In 65 patients in stage A, the median overall survival was 7.5 years for patients with high CLLU1 expression levels and not reached after 14.4 years for patients with low CLLU1 expression levels. (B) In 48 patients with mutated IgVH CLL the median overall survival was 7.6 years for patients with high CLLU1 expression levels and not reached after 14.4 years for patients with low CLLU1 expression levels. (C) In 43 patients with ZAP-70–positive CLL the median overall survival was 3.8 years for patients with high CLLU1 expression levels and 8.3 years for patients with low CLLU1 expression levels. (D) In 19 patients with CD38+ CLL the median overall survival was 3.3 years for patients with high CLLU1 expression levels and not reached after 11.3 years for patients with low CLLU1 expression levels.

Overall survival according to CLLU1 expression levels in different prognostic subgroups for patients younger than 70 years at diagnosis. (A) In 65 patients in stage A, the median overall survival was 7.5 years for patients with high CLLU1 expression levels and not reached after 14.4 years for patients with low CLLU1 expression levels. (B) In 48 patients with mutated IgVH CLL the median overall survival was 7.6 years for patients with high CLLU1 expression levels and not reached after 14.4 years for patients with low CLLU1 expression levels. (C) In 43 patients with ZAP-70–positive CLL the median overall survival was 3.8 years for patients with high CLLU1 expression levels and 8.3 years for patients with low CLLU1 expression levels. (D) In 19 patients with CD38+ CLL the median overall survival was 3.3 years for patients with high CLLU1 expression levels and not reached after 11.3 years for patients with low CLLU1 expression levels.

Close Modal

or Create an Account

Close Modal
Close Modal